Griffiths M R, Priestley G C
Department of Dermatology, University of Edinburgh, Scotland.
Acta Derm Venereol. 1992;72(1):15-8.
To study the effects of para-aminobenzoate on the dermis, fibroblast cell lines derived from lesions of lichen sclerosus et atrophicus, from morphoea and from normal skin were incubated with Potaba in vitro. Monolayer cultures containing Potaba showed a dose-dependent inhibition of proliferation beginning at 1,000 micrograms/ml with total inhibition at 10,000 micrograms/ml. Mean ID50 values for the three groups were not significantly different. There was a similar dose dependent inhibition of glycosaminoglycan secretion in all 3 groups, except at 10,000 micrograms/ml where secretion by lichen sclerosus et atrophicus and morphoea fibroblasts was significantly more inhibited than normal lines. Inhibition of the glycosaminoglycan secretion at 10-1,000 micrograms/ml was a direct effect of the drug rather than an indirect effect of changes in cell density, and lichen sclerosus et atrophicus fibroblasts produced about 40% more GAG than the morphoea or normal lines growing at similar densities. Collagen synthesis was increased in both lichen sclerosus et atrophicus and morphoea cell lines, with increased non-collagenous protein in morphoea lines. These results confirm that there are differences between lichen sclerosus et atrophicus and morphoea, and suggest glycosaminoglycan secretion as a possible target for the therapeutic action of Potaba.
为研究对氨基苯甲酸盐对真皮的影响,将取自硬化萎缩性苔藓、硬斑病及正常皮肤损害处的成纤维细胞系在体外与对氨基苯甲酸钾(Potaba)一起孵育。含有Potaba的单层培养物显示,从1000微克/毫升开始出现剂量依赖性的增殖抑制,在10000微克/毫升时完全抑制。三组的平均半数抑制浓度(ID50)值无显著差异。所有3组均出现类似的剂量依赖性糖胺聚糖分泌抑制,但在10000微克/毫升时,硬化萎缩性苔藓和硬斑病成纤维细胞的分泌抑制明显大于正常细胞系。在10 - 1000微克/毫升时对糖胺聚糖分泌的抑制是药物的直接作用,而非细胞密度变化的间接作用,并且在相似密度下生长的硬化萎缩性苔藓成纤维细胞产生的糖胺聚糖比硬斑病或正常细胞系多约40%。硬化萎缩性苔藓和硬斑病细胞系的胶原蛋白合成均增加,硬斑病细胞系中的非胶原蛋白增加。这些结果证实了硬化萎缩性苔藓和硬斑病之间存在差异,并表明糖胺聚糖分泌可能是Potaba治疗作用的靶点。